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Selective recruitment of protein kinases to the Hsp90
system is mediated by the adaptor co-chaperone
Cdc37. We show that assembly of CDK4 and CDK6
into protein complexes is differentially regulated by
the Cdc37-Hsp90 system. Like other Hsp90 kinase
clients, binding of CDK4/6 to Cdc37 is blocked
by ATP-competitive inhibitors. Cdc37-Hsp90 relin-
quishes CDK6 to D3- and virus-type cyclins and
to INK family CDK inhibitors, whereas CDK4 is relin-
quished to INKs but less readily to cyclins. p21CIP1
and p27KIP1 CDK inhibitors are less potent than
the INKs at displacing CDK4 and CDK6 from
Cdc37. However, they cooperate with the D-type cy-
clins to generate CDK4/6-containing ternary com-
plexes that are resistant to cyclin D displacement
by Cdc37, suggesting a molecular mechanism to
explain the assembly factor activity ascribed to
CIP/KIP family members. Overall, our data reveal
multiple mechanisms whereby the Hsp90 system
may control formation of CDK4- and CDK6-cyclin
complexes under different cellular conditions.
INTRODUCTION
A large proportion of the human kinome requires chaperoning
through the Hsp90 pathway to be activated and/or assembled
into functional complexes. Protein kinases are recognized
and bound by Cdc37, which acts as a gatekeeper to direct
this particular class of client proteins to Hsp90 (Prodromou
and Pearl, 2014). Molecular details of how Cdc37 recognizes
diverse protein kinase sequences have been elucidated
recently by determination of a structure of an Hsp90-Cdc37-
CDK4 complex by cryoelectron microscopy (Verba et al.,
2016). This structure confirms earlier studies that implicated
sequence features of the protein kinase N-terminal lobe and
ATP-binding cleft as contributing to the Cdc37 binding site
(Citri et al., 2006; Eckl et al., 2015; Polier et al., 2013; Xu1386 Cell Reports 21, 1386–1398, October 31, 2017 ª 2017 The Auth
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client kinases both during their initial folding and after they
have reached their mature state. It has been hypothesized
that the strength of this interaction is dictated in large part by
differences in the thermal and conformational stabilities of the
client protein (Taipale et al., 2012). From insights provided by
the Hsp90-Cdc37-CDK4 structure, it has been hypothesized
that these differences in stability manifest themselves as a dif-
ferential propensity of kinase domains to adopt an open state in
which the N- and C-terminal lobes are separated and can make
alternative interactions with Cdc37 and Hsp90 (Verba et al.,
2016). Indeed, Cdc37 has been proposed to sort client kinases
by testing their ability to resist local unfolding (Keramisanou
et al., 2016). Although weak client kinases can be hypothesized
to be proteins that readily escape Cdc37 because they have an
elevated stability, strong clients remain associated with Cdc37-
Hsp90 because they are metastable. As a result, they are held
in a protected state until relinquished to an appropriate partner.
Such a model would explain the observed ability of the Cdc37-
Hsp90 complex, through Cdc37, to both recognize diverse
protein kinase sequences with widely different affinities and
to sequester them until an appropriate binding partner is avail-
able (Boczek et al., 2015; Keramisanou et al., 2016; Verba
et al., 2016).
Members of the cyclin-dependent protein kinase (CDK) family
differ substantially in their dependency on the Cdc37-Hsp90
pathway (Taipale et al., 2012). CDKs that regulate the cell cycle
all require cyclin binding for full activity (Morgan, 2007). Given
the expression profiles of their cognate cyclins, the cell cycle
CDKs, CDKs 1, 2, 4, and 6, may exist during some stages of
the cell cycle in a non-cyclin-bound inactive state. Indeed, early
studies to purify CDK complexes identified monomeric CDK1
and CDK2 in cell extracts (Arooz et al., 2000; Gu et al., 1993).
In contrast, many CDK4 partner proteins function in pathways
that regulate protein folding and complex assembly, suggesting
that CDK4 may not be stable as a monomer (Jirawatnotai et al.,
2014). Consistent with these observations, CDK1 and CDK2
have no dependency on Cdc37-Hsp90, whereas CDK4 and
CDK6 are acknowledged Cdc37-Hsp90 client proteins (Lamp-
here et al., 1997; Parry et al., 1999; Smith et al., 2015; Stepanova
et al., 1996; Taipale et al., 2012). These observations suggestor(s).
commons.org/licenses/by/4.0/).
that monomeric CDK1 and CDK2 are relatively stable in the
absence of their cognate binding partners but that CDK4 and
CDK6 distribute into larger complexes that can include Cdc37
and Hsp90.
Cell cycle CDK-cyclin complexes are regulated by associa-
tion with members of two families of CDK inhibitors (CKIs)
(Hunter and Pines, 1994). The CIP/KIP family binds to both
the cyclin and CDK subunits to inhibit CDKs 1, 2, 4, and 6
(Russo et al., 1996), whereas members of the INK family specif-
ically bind to monomeric CDK4 and CDK6 (Brotherton et al.,
1998; Russo et al., 1998). Although the INK and cyclin D bind-
ing sites on CDKs do not overlap, INK binding alters the relative
disposition of the N- and C-terminal lobes of the CDK4 or
CDK6 kinase domain and, thus, through allostery, weakens
the CDK interaction with its cyclin partner (Brotherton et al.,
1998; Russo et al., 1998). In apparent contradiction to their
role as CDK inhibitors, members of the CIP/KIP family have
also been described as assembly factors that promote the for-
mation of CDK4/6-cyclin D complexes during G1 ((Bisteau
et al., 2013; Blain et al., 1997; Cheng et al., 1999; LaBaer
et al., 1997; Soos et al., 1996; Zhang et al., 1994; reviewed in
Sherr and Roberts, 1999), and, dependent on the state of CKI
phosphorylation, ternary CDK-cyclin-CKI complexes can be
catalytically active (Larrea et al., 2008; Ray et al., 2009). This
activity is also proposed to promote G1 progression by
sequestering CIP/KIP CKIs to create an environment in which
the activity of CDK2 can rise, driven by increasing cyclin
E expression (Sherr et al., 2016). Taken together, previous
studies suggest that the relative importance of these apparently
contradictory CKI roles in regulating cell cycle progression are
dependent on cell type and prevailing conditions.
The molecular details of how any client kinase is relinquished
by Cdc37-Hsp90 have not been elaborated. Cdc37-Hsp90 as-
sociation with CDK4 in vivo is mutually exclusive with either cy-
clin (Stepanova et al., 1996) or p16INK4a (Lamphere et al.,
1997) binding, suggesting that either protein might be a suitable
partner to which Cdc37-Hsp90 would transfer its client. In this
study, we set out to characterize the interactions of CDK4 and
CDK6 with the Cdc37-Hsp90 chaperone pathway and to deter-
mine whether known CDK binding proteins can displace CDK4
or CDK6 from Cdc37-Hsp90 complexes. We demonstrate in
cell-free assays that CDK4 and CDK6 can both interact with
Cdc37 and Cdc37-Hsp90 but differ considerably in their affin-
ities. CDK6 is a relatively weak client and can readily be dis-
placed from Cdc37 by members of the INK family or D-type
cyclins. CDK4, in contrast, is a strong client and binds tightly
to Cdc37 and to Cdc37-Hsp90. We show that Cdc37-Hsp90
will relinquish CDK4 to members of the INK family but not to
D-type cyclins. We find that cancer-associated p16INK4a mu-
tations differ in their modes of action toward CDK4 and CDK6
and in their abilities to displace CDK4 and CDK6 from Cdc37.
The CKIs p21CIP1 and p27KIP1 cooperate with the D-type cy-
clins to generate CDK4/6-containing ternary complexes that
are resistant to cyclin D displacement by Cdc37, suggesting
a molecular mechanism for CIP/KIP assembly factor activity.
Our results demonstrate that CDK4 and CDK6 are distin-
guished as clients of the Cdc37/Hsp90 system by cyclin and
INK partners.RESULTS
Monomeric CDKs Exhibit Differing Affinities for Cdc37
To evaluate whether the pattern of dependency on Cdc37-
Hsp90 that is observed in cells can be recapitulated with purified
proteins, CDKs 2, 4, and 6 were tested for their ability to bind to
Cdc37 in vitro. Using a homogeneous time-resolved fluores-
cence (HTRF) assay (Figure 1A), the measured affinities of
CDK4 and CDK6 for Cdc37 were approximately 90 nM and
greater than 500 nM respectively, whereas no interaction could
be detected between Cdc37 and CDK2 (Figure 1B; Table 1; Fig-
ure S1). The interactions were also tested using surface plasmon
resonance (SPR) immobilizing GSTCDK4 or GSTCDK6, and
similar affinities were measured (Figures S1C and 1D). These af-
finities are comparable with the value of approximately 200 nM
reported for the Cdc37-B-RafV600E kinase domain interaction,
measured by isothermal titration calorimetry (Polier et al.,
2013), and reinforce the idea that stable interaction with Cdc37
is the primary determinant of whether a kinase is an Hsp90 client.
As previously reported, CDK4 andCDK6 can be distinguished by
their affinities for Cdc37 (Stepanova et al., 1996; Taipale et al.,
2012). We next set out to determine how known CDK4/6 regula-
tors might affect the interactions between CDK4 and CDK6 with
Cdc37.
ATP-Competitive Inhibitors Antagonize the Interaction
between CDK4 or CDK6 and Cdc37
A general model has been proposed for the action of protein ki-
nase ATP-competitive inhibitors as agents that antagonize the
Cdc37-client protein kinase interaction, depriving the client of
access to the Hsp90 chaperone system and, thereby, promot-
ing its ubiquitylation and proteasomal degradation (Polier et al.,
2013). To test whether this model extends to CDK4 and CDK6,
we adapted the HTRF assay to run in a competition format.
ATP and three potent CDK4/6 inhibitors, PD0332991 (palboci-
clib), LEE011, (ribociclib), and LY2835219 (abemaciclib), with
measured half-maximal inhibitory concentration (IC50) values
against CDK4/6-cyclin D of 11/15 nM, 10/39 nM, and 2/5 nM,
respectively (values compiled in Sherr et al., 2016) were titrated
into pre-formed CDK4- or CDK6-Cdc37 complexes (Figures 1C
and 1D). All three inhibitors were able to displace Cdc37 from
CDK partners. PD0332991 is more potent than LEE011 at
displacing CDK4 and CDK6 from Cdc37, and against CDK6,
LY2835219 is as effective as PD0332991. CDK6 was more
readily displaced from Cdc37 than CDK4 by PD0332991 and
LEE011. ATP was unable to displace Cdc37 at physiological
(millimolar) concentrations (Figures S1E and S1F). Despite
repeated attempts, we were unable to derive reproducible
inhibition curves for the activity of LY2835219 toward CDK4-
Cdc37. This result suggests that the binding of LY2835219 to
CDK4 is not described by a straightforward reversible 1:1 inter-
action under our assay conditions or may interfere with the
assay. Taken together, these results support a model in which
Cdc37 and ATP-competitive inhibitor binding to CDK4 or CDK6
are mutually exclusive and suggest that CDK4/6-selective in-
hibitors also exert at least part of their therapeutic effects
through depriving CDK4/6 of access to the Cdc37-Hsp90
system.Cell Reports 21, 1386–1398, October 31, 2017 1387
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Figure 1. CDK4 and CDK6 Bind to Cdc37
(A) Homogeneous time-resolved fluorescence (HTRF) assay format.
(B) Cdc37 binding to CDK4 (blue line) and to CDK6 (red line) measured by HTRF. The concentration of CDK4 and CDK6 used in these assays was 10 nM. From
SPR titrations between GSTCDK4 or GSTCDK6 and Cdc37, it can be calculated that 34% and 20%, respectively, of the CDK4 and CDK6 are active (Figures S1C
and S1D).
(C and D) ATP-competitive inhibitors can displace Cdc37 from a CDK4-Cdc37 (C) or CDK6-Cdc37 (D) complex. CDK4 and CDK6 concentrations were 8 nM and
6 nM, respectively. HTRF measurements were carried out in duplicate and repeated on 3 separate days. The error bars indicate SD.
See also Figure S1.Cyclins DistinguishCDKs asClients of theCdc37/Hsp90
System
Cdc37 and cyclin D binding to CDK4 is mutually exclusive in cel-
lulo (Lamphere et al., 1997; Stepanova et al., 1996), suggesting
that D-type cyclins could be suitable partners to which the
Cdc37-Hsp90 complex would hand over its client CDK. Unfortu-
nately, recombinant monomeric cyclin D is unstable and prone
to aggregation, sowewere first obliged to use viral D-type cyclins
from Herpesvirus saimiri and Kaposi’s sarcoma-associated
herpesvirus (referred to as Vcyclin and Kcyclin, respectively) as
surrogates. These viral cyclins bind to CDK4 and CDK6 to pro-
mote their activity through G1 following viral infection (Li et al.,
1997;Swantonet al., 1997). Thecrystal structure ofCDK6-Vcyclin1388 Cell Reports 21, 1386–1398, October 31, 2017shows that cyclin engagement activates the CDK6 to form a het-
erodimer whose overall organization is reminiscent of activated
CDK2-cyclin A (Schulze-Gahmen and Kim, 2002). However, the
viral cyclin isdistinguished fromcyclinDby theabsenceof a cyclin
recruitment site that binds to the RXL recruitment motif that
assists binding of various substrates and CIP/KIP inhibitors
(Schulze-Gahmen and Kim, 2002; Swanton et al., 1997).
Using HTRF (Figures S2A and S2D) and SPR (Figures S2E and
S2F), both viral cyclins bind to CDK4 and to CDK6, albeit with a
slightly lower affinity for CDK4 (Table 1). To test whether the viral
cyclins can displace Cdc37 from a CDK-Cdc37 complex, gluta-
thione S-transferase (GST)-tagged CDK4 or CDK6was first incu-
bated with biotinylated C-terminally Avi-tagged Cdc37 and then
Table 1. Dissociation Constants for the Binding of Cdc37 and
Cyclins to CDK4 or CDK6
CDK4 CDK6
Cdc37 92 ± 29 460 ± 230a
Vcyclin 151 ± 11 14.9 ± 8.8
Kcyclin 24.9 ± 9.1 10.0 ± 3.5
The values (nanomolar) are derived from homogeneous time-resolved
fluorescence measurements. Errors represent the SD from the mean.
See also Figure S2.
aAnalyzed values are close to the signal-to-noise limited sensitivity of the
assay.titrated against increasing concentrations of unlabeled Vcyclin or
Kcyclin. Both viral cyclins were only just able to completely
dissociate a complex of CDK4-Cdc37 at the highest concentra-
tion assayed (1 mM; Figure 2A) but could relatively readily
displace CDK6 from a CDK6-Cdc37 complex (100% inhibition
achieved at concentrations around 100 nM; Figure 2B). Our re-
sults demonstrate that the viral cyclins can distinguish Cdc37-
CDK4 and Cdc37-CDK6 complexes and confirm that Cdc37
and cyclin binding to CDK4/6 is mutually exclusive.
We next tested whether, as would be predicted by the above
results and an equilibrium binding model, authentic D-type
cyclins relinquish CDK4 but not CDK6 when challenged with
increasing concentrations of Cdc37. FLAG-tagged Cdc37 was
bound to beads, incubated with either CDK4-cyclin D1 or D3
or CDK6-cyclin D1 or D3, and then the bound fractions were
analyzed by SDS-PAGE (Figure 2). Under these conditions,
CDK4 binds to the Cdc37 beads, and cyclin D1 and cyclin D3
cannot be detected in the pull-down complexes (Figure 2C).
This result suggests that the CDK4-cyclin D1/D3 complexes un-
dergo substantial reversible disassociation, allowing the CDK4
to redistribute into a complex with Cdc37. As would be predicted
from the behavior of CDK6 toward the viral cyclins, the CDK6-cy-
clin D3 complex was stable, and CDK6 binding to Cdc37was not
detectable (Figure 2D). However, the CDK6-cyclin D1 complex
showed a different pattern of activity: it resembles CDK4-cyclin
D1/D3 and undergoes detectable dissociation, resulting in the
formation of a CDK6-Cdc37 complex. Taken together, these
results show that cyclin D1 and cyclin D3 can be distinguished
by their respective activities in dissociating Cdc37-CDK4 and
Cdc37-CDK6 complexes.
We next sought to determine to what extent the presence of
Hsp90b affects the ability of a cyclin partner to disrupt the asso-
ciation of CDK4 and CDK6 with Cdc37. We assembled com-
plexes of CDK4 and CDK6 with Cdc37-Hsp90b in cells by trans-
fecting Spodoptera frugiperda (insect) cells with GSTCDK4 or
GSTCDK6 and untagged Cdc37(1–348). This strategy permits
the co-purification of GSTCDK-Cdc37 and GSTCDK-Cdc37-
Hsp90 complexes that incorporate the insect cell Hsp90 in stoi-
chiometric amounts (Vaughan et al., 2006). The high degree of
sequence similarity (>70%) between human and S. frugiperda
Hsp90 (SfHsp90) supports a model in which the insect protein
makes authentic interactions with the human CDK and Cdc37
proteins. Both binary and ternary complexes were purified by
first exploiting the GST tag and then by a subsequent size-exclu-sion chromatography step (Figures 2E and 2F, input lanes).
These GSTCDK-Cdc37 and GSTCDK-Cdc37-SfHsp90 com-
plexes were then characterized in a pull-down assay using Avi-
tagged D-type cyclins as the bait protein. The patterns of
CDK4 andCDK6 behavior bound to Cdc37 or to Cdc37-SfHsp90
are similar in this pull-down assay. Kcyclin could extract CDK6
from CDK6-Cdc37 and CDK6-Cdc37-SfHsp90 (Figure 2F). The
binary and ternary CDK4 complexes were refractory to disrup-
tion (Figure 2E). To confirm that the CDK6-Kcyclin complex
that was generated following viral cyclin capture of the CDK6
was authentic, its kinase activity was tested using retinoblas-
toma protein (Rb) as a substrate (Figure S2I). CDK6-Kcyclin
displayed robust activity toward Rb, as measured by phosphor-
ylation of S780.
Taken together, these results demonstrate that cyclins can
distinguish CDKs as clients of the Cdc37/Hsp90 system. They
suggest that cyclin D1 and cyclin D3 have more comparable af-
finities for CDK4 than CDK6 and that cyclin D3 binds more tightly
to CDK6 than cyclin D1. The ability of cyclins to displace their
cognate CDKs from Cdc37 can be understood in terms of the
relative affinities of each CDK for Cdc37 and cyclin partners.
This model predicts that, in a cellular context, the efficiency of
CDK4 and CDK6 displacement from Cdc37 will depend on the
identity and concentration of the competing cyclin.
CKIs Also Distinguish CDKs as Clients of the Cdc37/
Hsp90 System
Members of the CIP/KIP and INK families of CKIs also bind to
CDKs and might also be partners to which the Cdc37 would
hand over the CDK. Using the HTRF assay, we determined
that CDK4 and CDK6 bind tightly to p16INK4a, with Kd values
in the low nanomolar range. However, because these dissocia-
tion constants correspond to less than the concentration of
bait (GSTCDK) used in the HTRF assay, they represent upper
estimates for the affinity of each interaction. To determine
more accurate Kd values, we re-evaluated the interactions by
SPR (Figures S3A and S3B; Table 2). In these experiments,
GSTCDK4 or GSTCDK6 was captured on the chip, and un-
tagged p16INK4a was flowed over as the ligand. The accuracy
of the Kd values determined by fitting the kinetic curves (kon,
koff) are compromised by the accuracy with which koff can be
determined. However, they do indicate very tight association
with calculated Kd values of 0.87 ± 0.42 nM and 0.26 ± 0.16,
respectively, for the CDK4- and CDK6-p16INK4a interactions.
We then assayed the abilities of the four authentic INK proteins
to displace Cdc37 from CDK4- or CDK6-Cdc37 complexes.
Addition of increasing concentrations of each authentic INK to
CDK4-Cdc37 (Figure 3A) or CDK6-Cdc37 (Figure 3B) resulted
in a loss of fluorescent signal, demonstrating that INK and
Cdc37 binding to CDK4 and CDK6 is mutually exclusive. In this
assay, the determination of the Kd values is again limited by
the component concentrations so that, in each case, the ability
of the authentic INK to displace Cdc37 from a CDK-Cdc37 com-
plex can be given an upper value of approximately 8 or 6 nM,
respectively (which is the concentration of the GSTCDK4 or
GSTCDK6 component used in the assay). To confirm the activity
of p16INK4a toward the CDK4/6-Cdc37 interaction in the
context of a complex with Hsp90, the GSTCDK-Cdc37 andCell Reports 21, 1386–1398, October 31, 2017 1389
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Figure 2. Cyclin and Cdc37 Binding to CDKs Are Mutually Exclusive
(A and B) Kcyclin (red) and Vcyclin (blue) readily displace Cdc37 from CDK6 (B) but not from CDK4 (A). The concentrations of CDK4- and CDK6-containing cyclin
D complexes used in the assays were 8 nM (CDK4) and 6 nM (CDK6), respectively. HTRFmeasurements were carried out in duplicate and repeated on 3 separate
days. The error bars indicate SD.
(C and D) FLAG-tagged Cdc37 was co-incubated with CDK4-cyclin D1/D3 (C) or CDK6-cyclin D1/D3 (D) and then analyzed by SDS-PAGE and subsequent
InstantBlue staining. The upper band present in the CDK6-cyclin samples is CDK6, whereas the lower band is the cyclin D. The upper band of the CDK4-cyclin D1
complex is cyclin D1, whereas the lower band is CDK4. CDK4 and cyclin D3 have very similar masses and, when analyzed together, are not resolved. Inputs are
marked by the black bars above the right hand side lanes. CDK4, but not cyclin D1 or D3, is detected bound to the FLAG-tagged Cdc37 beads (C), indicating that
Cdc37 has displaced CDK4 from either cyclin partner. In contrast, CDK6 is not detectable bound to Cdc37 when bound to cyclin D3 but is displaced from cyclin
D1 following incubation with Cdc37 (D).
(legend continued on next page)
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Table 2. Characterization of p16INK4a and p16INK4a Mutants
CDK4 (Kd, nM) CDK6 (Kd, nM) Tm (
C) DTm (versus p16INK4a) (C)
p16INK4a 0.87 ± 0.42 0.26 ± 0.16 47.5 (±1.9) 0.0
p16D84N ND 59.7 ± 12.0 45.1 (±1.9) 1.8 (±0.10)
p16D108N 2.56 ± 0.49 0.28 ± 0.10 36.4 (±3.1) 10.5 (±1.29)
p16M53I ND 0.73 ± 0.15 42.7 (±0.47) 4.9 (±2.33)
p16M53E ND 1.56 ± 0.19 43.2 (±0.38) 4.6 (±1.66)
Dissociation constants for the binding of wild-type p16INK4a and eachmutant to CDK4 or CDK6 are derived fromSPRmeasurements. The Tm for wild-
type p16INK4a and each mutant was determined by DSF. Errors represent the SD from the mean. ND, not determined. See also Figure S3.GSTCDK-Cdc37-SfHsp90 complexes purified from insect cells
were characterized in a pull-down assay using Avi-tagged
p16INK4a as the bait protein. Confirming the earlier results,
Avi-tagged p16INK4a was able to displace both CDK4 and
CDK6 from complexes containing Cdc37 and Cdc37-SfHsp90
(Figures 3C and 3D).
Mutant forms of p16INK4a are associated with cancer sus-
ceptibility (see http://www.tumorportal.org) and would be pre-
dicted to have reduced affinity for CDK4 or CDK6. We reviewed
the missense CDKN2A sequences compiled at http://www.
tumorportal.org and selected the following p16INK4a residues
for further study: M53, D84, and D108. These residues are
frequently mutated, and, as inferred by inspection of the crystal
structure of CDK6-p16INK4a, they would be predicted to inter-
fere with the p16INK4a-CDK interaction (Brotherton et al.,
1998). Indeed, p16D84N, in which D84 is mutated to an aspara-
gine (Ruas et al., 1999), and p16M53I, in whichM53 ismutated to
an isoleucine (Harland et al., 1997), have been reported to show
reduced binding to CDK4 and to CDK6.
We first confirmed this activity for p16D84N. SPR allowed a
direct quantitative comparison and highlights the rapid dissocia-
tion rate that is an acquired characteristic of this mutant, leading
to a significant reduction in its binding to both CDK4 (binding
could be detected but not quantified) and CDK6 (Kd, 60 nM)
(Figures S3C and S3D; Table 2). Loss of this aspartate side chain
removes a key hydrogen bond to R31 of CDK6 or R24 of CDK4,
a residue that is also mutated in several cancer types (Smith-
Sørensen and Hovig, 1996; http://www.tumorportal.org).
Differences in the affinity of p16M53I toward CDK4 and CDK6
are also apparent (Figures S3E and S3F; Table 2). Binding of the
p16M53I mutant to CDK4 and CDK6, measured by SPR, had kon
values comparable with those of wild-type p16INK4a, whereas
the dissociation rates of the mutant protein complexes differed
markedly from those of wild-type p16 and depended also on
the identity of the CDK. Comparedwith wild-type p16INK4a (Fig-
ure S3B), p16M53I showed an approximately 10-fold higher rate
of dissociation from CDK6 (Figure S3F), and its dissociation from
CDK4 was substantially increased (Figure S3E). Taking the SPR
results together, the p16M53I mutant has a similar affinity for(E and F) Kcyclin binds to CDK4 (E) and CDK6 (F) and is able to displace CDK6
assembled in insect cells. The uncropped gels that include the control lanes to co
tagged beads are included as Figures S2G and S2H. Inputs are marked by the bla
and subsequent InstantBlue staining.
See also Figure S2.CDK6 (Kd 0.73 ± 0.15 nM) as p16INK4a (Kd 0.26 ± 0.16 nM)
but a much reduced affinity for CDK4 (binding could be detected
but not quantified; Table 2). A p16M53E mutant was also as-
sayed by SPR (Figures S3G and S3H; Table 2) and showed
equivalent behavior. Methionine 53 lies at the INK-CDK6 inter-
face, where its side chain points into the CDK6 active site toward
a conserved aspartate (CDK6 D104, CDK4 D99) that sits below
the ribose hydroxyls of ATP (PDB: 1BI7, Russo et al., 1998;
1BI8, Brotherton et al., 1998).
In contrast, the activity of p16D108N (D108 mutated to an
asparagine) was very similar to that of p16INK4a (Figures S3I
and S3J; Table 2). Based on these results, we hypothesized
that reduced protein stability might mediate this mutant’s ef-
fects. To test this hypothesis, we used differential scanning fluo-
rimetry (DSF) to determine the melting temperature values for
each of the p16INK4a species (Table 2). Authentic p16INK4a is a
stable protein (Tm 47.5
C ± 1.9C), and the introduction of muta-
tionsM53I andD84N resulted in small destabilizations (Tm values
of 42.7C ± 0.47C and 45.1C ± 1.9C, respectively). However,
DSF reveals that the p16D108N mutant is distinguished by
its significantly depressed melting temperature (Tm value of
36.4C ± 3.1C) relative to p16INK4a. This result suggests that
this mutation destabilizes p16INK4a, leading to reduced levels
of expression rather than inhibiting the interaction with CDK4
or CDK6.
Presuming an equilibrium binding model, a hypothesis that
can be proposed from our results is that p16INK4a mutants
will differ in their abilities to displace Cdc37 from CDK4 and
CDK6. To test this hypothesis, we assayed the p16INK4a mu-
tants in the HTRF displacement assay (Figures 3E and 3F).
p16D84N and p16D108N behaved as expected: p16D84N was
unable to displace CDK4 or CDK6 from Cdc37 (Figures 3E and
3F, gray curves), whereas p16D108N was as effective as wild-
type p16INK4a in displacing CDK6 (Figure 3F, blue curve) and
showed only a modest reduction in activity toward CDK4
(Figure 3E, blue curve). In agreement with our hypothesis,
p16M53I is as effective as authentic p16INK4a at displacing
Cdc37 from CDK6 (Figure 3F, cyan curve) but is ineffective at
displacing Cdc37 from CDK4 (Figure 3E, cyan curve).(F) but not CDK4 (E) from CDK-Cdc37 and CDK-Cdc37-Hsp90b complexes
nfirm that CDK4, CDK6, Cdc37, and Hsp90 do not stick non-specifically to Avi-
ck bars above the right hand side lanes. Samples were analyzed by SDS-PAGE
Cell Reports 21, 1386–1398, October 31, 2017 1391
A B
C D
E F
Figure 3. CKI-Mediated Displacement of Cdc37 from CDK4-Cdc37 and CDK6-Cdc37 Complexes
(A and B) Displacement of Cdc37 from CDK4 (A) or CDK6 (B) by members of the INK family.
(C and D) p16INK4a is able to displace CDK4 (C) and CDK6 (D) from CDK-Cdc37 and CDK-Cdc37-Hsp90b complexes assembled in insect cells. The uncropped
gels that include the control lanes to confirm that CDK4, CDK6, Cdc37, and Hsp90 do not stick non-specifically to Avi-tagged beads are included as Figure S4.
(E and F)Mutant p16INK4a varies in its ability to displace Cdc37 from aCDK4-Cdc37 complex (E) or a CDK6-Cdc37 complex (F). The concentrations of CDK4 and
CDK6 were 8 nM and 6 nM, respectively.
The HTRFmeasurements presented in (A) and (B) were carried out in duplicate and repeated on 3 separate days. Themeasurements presented in (C) and (D) were
carried out in duplicate and independently repeated twice. The error bars indicate SD. See also Figures S3 and S4.Taken together, these results suggest that not all p16INK4a
mutations detected in tumor cells act through the same mecha-
nism. The observation that p16M53I is as effective at binding to
CDK6 as the authentic p16INK4a sequence suggests that this
mutation may only be effective in settings where cell cycle pro-
gression is driven by CDK4. Furthermore, it can be hypothesized
that clinically significant changes to the p16INK4a sequence
might not only affect the regulation of CDK4 and CDK6 activity1392 Cell Reports 21, 1386–1398, October 31, 2017by affecting the direct binding of p16INK4a but also by affecting
the ability of p16INK4a to inhibit the interactions of CDK4 and
CDK6 with their regulators.
CDK-Cyclin D Complexes Selectively Resist Disruption
by Cdc37 in the Presence of p21CIP1 or p27KIP1
Members of the CIP/KIP family have been proposed to act as
assembly factors for CDK4/6-cyclin D complexes during G1.
As demonstrated above, D-type cyclin alone is unable to
displace Cdc37 from CDK4, and CDK4 bound to cyclin D1 or
D3 or CDK6 bound to cyclin D1 redistribute into complexes
containing Cdc37. From these results, we hypothesized that
addition of p21CIP1 or p27KIP1 might stabilize CDK4/6-cyclin
D complexes relative to Cdc37 or Cdc37-Hsp90 complexes
with CDK4 or CDK6.
Using the HTRF assay, we first observed that full-length
p27KIP1 (p27FL) displaced Cdc37 from CDK4-Cdc37 or
CDK6-Cdc37, albeit significantly less efficiently than the INKs
(Figures 4A and 4B). The crystal structure of a CDK2-cyclin
A-p27KIP1 complex reveals that the N-terminal sequence of
p27KIP1 has a significant interaction with the CDK N-terminal
lobe that might explain this activity (Russo et al., 1996). Accord-
ingly, constructs related to the co-crystallized fragment of
p27KIP1 (residues 1–106, termed p27M) and to that part of the
construct that was resolved in the electron density of that com-
plex (p27KIP1 residues 23–106, termed p27S) were assayed for
their ability to displace Cdc37 from CDKs 4 and 6. We also as-
sayed corresponding fragments of p21CIP1 (p21M/S, residues
1/9–87). Each of these constructs retains the ability to displace
Cdc37 (Figures 4A and 4B), suggesting that Cdc37 displacement
activity resides in residues contained within the ‘‘S’’ fragment
constructs of CIP/KIP proteins. However, p27FL was the most
potent p27KIP1 construct tested and showed equivalent activity
toward CDK4 and CDK6, suggesting that additional p27KIP1
residues C-terminal to residue 106 may contribute to Cdc37
displacement.
To find out whether the CIP/KIP CKIs can cooperate with cy-
clin D isoforms to generate a stable ternary CDK4 complex
that is resistant to displacement by Cdc37, we next purified
GSTCDK4-cyclin D1 and D3 and GSTCDK6-cyclin D1 and D3
complexes assembled in insect cells, incubated them with
excess p21M or p27M, and isolated the complexes by size-
exclusion chromatography. We then used the HTRF assay to
measure the association of Avi-tagged Cdc37 with GSTCDK4
and GSTCDK6, which were presented unpartnered, in a binary
complex with cyclin D1 or cyclin D3, or in a ternary complex
with cyclin D1 or D3 and p21M, or p27M. As shown previously,
Cdc37 binds to monomeric CDK4 (Figures 4C and 4E, blue lines)
and effectively displaces cyclin D1 or cyclin D3 (Figures 4C and
4E, red lines). However, addition of p21M or p27M to CDK4-cy-
clin D3 (Figure 4E, magenta and green lines, respectively) or
addition of p27M to CDK4-cyclin D1 (Figure 4C, green line)
prevent Cdc37 from binding, suggesting that cyclin D isoforms
and the CIP/KIP CKIs cooperate to generate a stable ternary
CDK4 complex that is resistant to displacement by Cdc37.
As demonstrated above, Cdc37 binds to free CDK6 (Figures
4D and 4F, blue lines) and, as expected, was less effective at ex-
tracting CDK6 from complexes with cyclin D3 (Figure 4F, red
line). CDK6-cyclin D3-p27M was refractory to disruption (Fig-
ure 4F, green line). Again, cyclin D1 and D3 are distinguished:
cyclin D1, unlike cyclin D3 and the viral D-type cyclins, forms
a complex with CDK6 that is disrupted by Cdc37 (Figure 4D,
red line). Addition of p27M can stabilize it (Figure 4D, green
line). These results suggest that activation of CDK4 and CDK6
by D-type cyclins can be distinguished by their requirement
for the assembly function of p21CIP1 or p27KIP1. We hypothe-size that the CIP/KIP proteins assist CDK4 and CDK6 to re-
distribute from Cdc37 complexes into stable complexes with
cyclin D1. Formation of complexes of CDK6 with cyclin D3
and the viral D-type cyclins, by contrast, are less dependent
on this mechanism.
DISCUSSION
Protein kinases differ in their apparent affinity for Cdc37, and it
has been hypothesized that the strength of this interaction re-
flects the inherent stability of the client kinase fold (Taipale
et al., 2012) (Keramisanou et al., 2016). However, the simple
reversibility of the interaction with Cdc37 in vitro and the ability
of this interaction to be inhibited by small-molecule ATP-
competitive kinase inhibitors (Polier et al., 2013) strongly suggest
that recruitment to the Cdc37-Hsp90 system ismore about regu-
lation than protein folding (Keramisanou et al., 2016; Verba et al.,
2016). Client kinases recruited to Cdc37-Hsp90 complexes are
thought to undergo repeated cycles of release and recapture
driven by the Hsp90 ATPase-coupled chaperone cycle until
they escape the cycle through achieving an active state and/or
by finding an appropriate partner (Prodromou and Pearl, 2014).
Alternatively, when the chaperone ATPase cycle is blocked,
the kinase becomes ubiquitylated and subsequently degraded
by the proteasome (Butler et al., 2015; Krukenberg et al., 2011;
Neckers and Workman, 2012). We have shown that ATP-
competitive drugs targeting CDK4/6 have a shared mechanism
of action with small-molecule inhibitors of other Hsp90-depen-
dent kinases (Polier et al., 2013) and block Cdc37 binding to
deprive CDK4 and CDK6 of access to the Hsp90 chaperone
system. It is yet to be determined whether enhanced CDK4/6
degradation through the proteasome system may also be an
unintended but therapeutically valuable consequence of the ac-
tion of CDK4/6 inhibitors or whether alternative dysregulated
pathways emerge (Paternot et al., 2014; Polier et al., 2013).
The central hypothesis of this paper is that much of the
behavior of CDK4/6 in respect of their interactions with Cdc37-
Hsp90 can be explained by thermodynamic partitioning between
chaperoned (in complex with Cdc37with or without Hsp90), acti-
vated (in complex with cyclins), and inhibited (in complex with
INK) complexes (Figure 5). CDK4 and CDK6 can reversibly asso-
ciate with Cdc37 in a state that is poised for displacement by
CDK regulators. The recently published structure of a CDK4-
Cdc37-Hsp90 complex supports this model and reveals, at least
for CDK4, that the poised state is one in which the kinase is
considerably unfolded (Verba et al., 2016). As a prediction of
this structural model, it was proposed that rising cyclin D con-
centrations could provide sufficient stabilization energy so that
unfolded CDK4 would be displaced from Cdc37 to form a folded
CDK4-cyclin D complex. Our results extend this model to show
that CDK4 and CDK6 are distinguished as Cdc37 clients by their
differing affinities and that differences in the affinities of CDK reg-
ulators (INKs versus cyclin D1 versus cyclin D3) for CDK4 and
CDK6 have the potential to affect CDK4 and CDK6 displacement
from Cdc37 to create a network of finely tuned signaling interac-
tions to regulate CDK4 and CDK6 activity.
We demonstrate that the different authentic INK proteins bind
tightly to CDK4 and CDK6 and are highly effective at displacingCell Reports 21, 1386–1398, October 31, 2017 1393
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Figure 4. p21CIP1 and p27KIP1 Cooperate with Cyclin D to Prevent Cdc37 Association with CDK4 and CDK6
(A and B) p27KIP1FL (p27FL), p21CIP1S/M (p21S, p21M), and p27KIP1S/M (p27S, p27M) can displace CDK4 (A) or CDK6 (B) from Cdc37.
(C and D) Cdc37 binds to CDK4 (C) or CDK6 (D) (blue curves) and can effectively displace cyclin D1 (red curves). Upon addition of excess Cdc37, the ternary CDK-
cyclin D1-p27KIP1M complexes do not redistribute to form CDK-Cdc37 (green curves).
(E) Cdc37 binds to CDK4 (blue) and can effectively displace cyclin D3 bound to CDK4 (red). Upon addition of excess Cdc37, ternary complexes of CDK4-cyclin
D3-p27KIP1M or p21CIP1M do not redistribute to form CDK4-Cdc37 (green and magenta curves, respectively).
(F) In contrast, CDK6 binds to Cdc37 (blue curve) but cannot be displaced from cyclin D3 by Cdc37 (red curve).
All HTRF measurements were carried out in duplicate and repeated. The error bars indicate SD.
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Figure 5. Exchange of CDKs into and out of Com-
plexes Containing Cdc37
The experiments reconstitute the redistribution of CDKs 4
and 6 (blue) between complexes that contain Cdc37 (coral)
and complexes that contain other binding partners drawn
from ATP-competitive inhibitors (red), cyclins (green), CIP/KIP
family CKIs (yellow), and INK family CKIs (purple). Boxed half
arrows indicate the half reactions of these equilibria that have
been reconstituted in the present study. Smaller arrows in
the ‘‘reverse’’ direction (i.e., toward complexes that contain
Cdc37) indicate reactions where the competitor appears to
bind to CDKs substantially more tightly than does Cdc37.
Partitioning between the different partnered states is pre-
sumed to proceed via unbound states of the kinase, which
exist in an equilibrium between less folded ‘‘open’’ states
(which preferentially bind to the chaperone system) and more
folded ‘‘closed’’ states (which preferentially bind to the other
partners).CDK4 or CDK6 fromCdc37-Hsp90b. We also show that clinically
relevant INK mutants can be selected in cancer cells that inacti-
vate CDK4 and CDK6 through different mechanisms and, as a
result, also show differing abilities to displace Cdc37 bound to
CDK4 or CDK6.
The behavior of p16D84N and p16D108N, both as CDK4/6
binding proteins and as partners to which the Cdc37-Hsp90
chaperone system will relinquish their CDK4 or CDK6 clients,
can be rationalized, respectively, by their location at the INK-
CDK interface (D84N) and effect on INK stability (D108N).
p16D84N has previously been reported to inhibit CDK4-cyclin
D1 kinase activity as effectively as wild-type p16INK4a and
to be modestly less effective at inhibiting G1 progression
(Koh et al., 1995). Taken together, these results suggest that
p16INK4a mutations can exert their effects by altering the equi-
librium distribution of p16INK4a between multiple CDK4- and
CDK6-containing complexes.
Mutations to p16INK4a residue M53 showed unexpected
behavior, distinguishing CDK4 and CDK6. This mutant is equiv-
alent to wild-type p16INK4a in its affinity for CDK6 but displays
an enhanced koff rate toward CDK4, resulting in a >10
6-fold
reduction in the strength of the interaction. As a result,
p16M53I is as effective as authentic p16INK4a in its ability to
displace CDK6 from a preformed CDK6-Cdc37 complex but
has amuch reduced ability to displace CDK4 fromCdc37. These
results suggest that the disease-associated activity of this
mutant may be manifested primarily through its activity toward
CDK4. This behavior has also been reported for another
p16INK4a mutant also identified in familial melanoma in which
R24 is mutated to a proline (Jones et al., 2007).Cyclins, however, display a range of efficiencies.
As expected, this spectrum of cyclin D activity fa-
vors CDK6-cyclin complexes because CDK6 is a
weaker Cdc37-Hsp90 client. In the presence of viral
cyclins or cyclin D3, CDK6 partitions from a chaper-
oned into a cyclin-bound complex. In the presence
of cyclin D1, however, we observed different
behavior. Specifically, we found that CDK6 sponta-
neously redistributes from cyclin D1 into a CDK6-Cdc37-Hsp90 complex, suggesting that the affinity of cyclin
D1 for CDK6 is not sufficient to overcome that of Cdc37-
Hsp90. CDK4 however, is a strong Cdc37-Hsp90 client, and as
a result, no cyclins tested were able to partition the CDK4
away from Cdc37-Hsp90. These results suggest a fine-tuning
of the system to distinguish the affinities of different cyclin D iso-
forms toward CDK4 andCDK6. This situation changes, however,
when the cyclin is partnered by either p21CIP1 or p27KIP1.
Although these CKIs are inefficient at displacing Cdc37 from
CDK4/6 when alone, when present with either cyclin D1 or cyclin
D3, they form a stable ternary complex that is resistant to redis-
tribution of the CDK into a Cdc37-Hsp90 complex. We have pro-
vided direct evidence that p27KIP1 can perturb the distribution
of CDKs between Cdc37-containing and cyclin-containing com-
plexes in experiments that reconstitute the reverse reaction.
Because the results presented in this paper demonstrate that
both forward and reverse reactions can occur spontaneously,
it is reasonable to infer that inhibition of the reverse reaction is
functionally equivalent to promoting the forward reaction, an
equilibrium model that is consistent with an analysis of the
CDK4-Cdc37-Hsp90 structure (Verba et al., 2016). We hypothe-
size that this behavior provides a potential molecular mechanism
for thewell documented activity of p21CIP1 and p27KIP1 as ‘‘as-
sembly factors’’ for CDK4/6-cyclin D-containing complexes
during G1.
We propose that other CDK4 and CDK6 regulators may be
able to displace both CDK4 and CDK6 from Cdc37. Such a
model has been proposed from cell-based studies (Sugimoto
et al., 2002). Our in vitro experiments complement this approach
and provide a more quantitative assessment of the differentCell Reports 21, 1386–1398, October 31, 2017 1395
molecular interactions involved. The differences we observe in
the interplay of CDK4 and CDK6 and their partners with the com-
ponents of the Hsp90 system could explain the apparently con-
tradictory studies in mouse embryonic fibroblasts (MEFs) that
have addressed the roles of CKIs in assembling CDK4 and
CDK6 complexes. MEFs lacking p21CIP1 and p27KIP1 have
been reported to fail to assemble CDK4/6 complexes (Cheng
et al., 1999), to assemble them but to a much lower level (Sugi-
moto et al., 2002), or to assemble them under conditions where
cyclin D levels were elevated (Bagui et al., 2003). In another study
in HCT116 cells, overexpression of Cdc37 suppressed CDK4
binding to p16 but enhanced CDK4 binding to cyclin D (Zhao
et al., 2004).
Taken together with our results, a unifying model is that the
CIP/KIP and INK families of CDK inhibitors may each play a
role in CDK4/6-cyclin D assembly. For INKs, this role would
be mediated by their ability to compete with cyclins to displace
CDKs from Cdc37, whereas for CIP/KIPs, the role would be
through assisting cyclin D in sequestering CDKs from Cdc37.
It can be hypothesized that CDK4 and CDK6 differ in their re-
quirements for the CKIs to act as assembly factors. Our results
support a model in which CDK6 is handed over from Cdc37 to
form a relatively stable CDK6-cyclin D3 complex. At the other
extreme, the weaker affinity of CDK4 for cyclin D1 or cyclin
D3, coupled with the higher affinity of CDK4 for Cdc37, sug-
gests a greater dependency on CKI assembly factor activity
and/or a requirement for higher cyclin D concentrations before
Cdc37 would hand over this CDK to its activating partner. We
note that CDK4/6-cyclin D1 complexes remain relatively unsta-
ble, suggesting that they may be susceptible to continued
exchange between cyclin and Cdc37 partners unless their sub-
sequent modification acts to stabilize them. Given that cyclin
D1 is the most widely expressed cyclin D in different cell types
and is most frequently implicated as a cancer driver in solid tu-
mors (Baker and Reddy, 2012), we hypothesize that, in many
clinical settings, activation of CDK6 may be enhanced by the
assembly function of p21CIP1 or p27KIP1. Our results further
suggest that a subset of p16INK4a mutations will be most
detrimental in cancer settings driven by CDK4. Finally, we
note that other CDK4/6 regulators and /or CDK4/6 phosphor-
ylation may also provide additional stabilization energy to
displace CDK4 or CDK6 from Cdc37, providing multiple oppor-
tunities for the Cdc37-Hsp90 chaperone system to fine-tune
CDK4 and CDK6 activities.
EXPERIMENTAL PROCEDURES
Protein Expression
Proteins were expressed in recombinant E. coli cells or in Sf9 insect cells using
a recombinant baculovirus expression system (Bieniossek et al., 2012) and pu-
rified by sequential affinity and size-exclusion chromatography.
Interaction Assays
Pull-down assays were conducted at 4C with the target protein present in a
3-fold molar excess to the bait and visualized by SDS-PAGE and subsequent
staining with InstantBlue. For HTRF assays, one of the interacting partners was
purified as a GST fusion, whereas the other was expressed with an Avi tag to
allow subsequent biotinylation. Interactions between the partners gave rise to
a fluorescent signal because of developing reagents comprising a turbium-
conjugated anti-GST antibody and the fluorescent dye SAXL665 coupled to1396 Cell Reports 21, 1386–1398, October 31, 2017streptavidin. For competition HTRF assays, binary complexes were estab-
lished with one partner present in trace concentrations and the other poised
at its apparent Kd. Competitors were titrated across a range of concentrations,
and their competitive binding was observed as a loss of fluorescence reso-
nance energy transfer (FRET) signal. For SPR assays, CDK4 and CDK6 were
immobilized as GST fusions on a chip via anti-GST antibody coupling and
exposed to dilution series of the various ligands. Kd values were derived
from fitting the binding and dissociation curves to derive kon and koff rates.
Data were analyzed either using GraphPad Prism version 6 (GraphPad)
(HTRF) or Biacore S200 evaluation software (SPR).
DSF
Thermal melting experiments to determine Tm values for wild-type and mutant
p16INK4a proteins were carried out essentially as described previously (Matu-
lis et al., 2005).
Detailed protocols for all the methods are provided in the Supplemental
Experimental Procedures.
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Figure S1. Related to Figure 1. Evaluation of CDK binding to Cdc37 and ATP. (A) CDK2 binding to Cdc37. The 
binding of full length authentic Cdc37 to CDK2 was tested by homogeneous time resolved fluorescence. Cdc37 does 
not bind to CDK2. The glutathione-S-transferase-CDK2 (GSTCDK2) concentration was 25 nM and measurements were 
carried out in duplicate. (B) Cdc37 does not bind to GST. The experiment in panel (A) was repeated replacing 
GSTCDK2 with GST (25 nM). In both panels, the error bars indicate standard deviation. (C, D) CDK4 (C) and CDK6 
(D) binding to Cdc37 as measured by surface plasmon resonance. GSTCDK4 and GSTCDK6 were immobilized on the 
chip via anti-GST antibody coupling and the Cdc37 ligand was assayed in triplicate over a 5-point serial dilution (4000 
nM, 2000 nM, 1000 nM, 250 nM and 62.5 nM). Dissociation constants (CDK4, Kd = 347 ± 30 nM; and CDK6, Kd = 
7000 ± 4500 nM) were derived by using the Biacore S200 Evaluation Software. (E, F) ATP does not displace Cdc37 
from CDK4 (E) or CDK6 (F).  The ATP was dispensed in a two-fold dilution series starting at 2 mM. DMSO was 
added at 0.5% (E) or 0.01% (F). The concentrations of GSTCDK4 and GSTCDK6 were 8 nM and 6 nM respectively. 
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Figure S2. Related to Figure 2. 
Kcyclin and Vcyclin bind to CDK4 and CDK6. (A-D) Homogeneous Time Resolved Fluorescence (HTRF) to 
measure the binding of Kcyclin (A, B) and Vcyclin (C, D) to CDK4 (A, C) and CDK6 (B, D). The concentrations of 
GSTCDK4 and GSTCDK6 were 10 nM. HTRF measurements were carried out in duplicate and repeated twice on two 
separate days. The error bars indicate standard deviation.  (E, F) Surface Plasmon Resonance (SPR) to measure the 
binding of Vcyclin to CDK4 (E) and CDK6 (F). GSTCDK4 and GSTCDK6 were immobilized on the chip via anti-
GST antibody coupling and the Vcyclin ligand was assayed in triplicate over a 5 point serial dilution (500 nM, 250 nM, 
62.5 nM, 15.6 nM and 4 nM). Curves were evaluated using the Biacore S200 Evaluation Software. Although binding 
was detectable between CDK4 and Vcyclin (E), the data quality precluded calculation of a Kd. The dissociation 
constant for the interaction between CDK6 and Vcyclin (Kd = 0.016  ±  0.013 nM) was derived by using the Biacore 
S200 Evaluation Software. (G, H) SDS-PAGE gels to accompany Figure 2E, F to confirm that CDK4 and CDK6 do not 
bind non-specifically to Avi-beads. Bars above the gels indicate inputs. Samples were visualized by InstantBlue 
staining. (I) CDK6-Kcyclin assembled following Kcyclin displacement of CDK6 from CDK6-Cdc37 is catalytically 
active. CDK6 activity was measured against retinoblastoma protein (pRb). A full description of the kinase assay is 
included in the Supplemental Experimental Procedures. Phosphorylated pRb was detected by an anti-phosphorylated 
S780 Ab (Abcam). 
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Figure S3.  Related to Figure 3. p16INK4a binding to CDK4 and CDK6 measured by surface plasmon 
resonance. Binding of p16INK4a and p16INK4a mutants to CDK4 (A, C, E, G, I) and CDK6 (B, D, F, H, J) by SPR. 
GSTCDK4 or GSTCDK6 were immobilized on the chip via anti-GST antibody coupling and p16INK4a proteins were 
flowed over in a 5-point dilution series (200nM, 100 nM, 25 nM, 6.25 nM, and 1.56 nM). Kd values were derived using 
the Biacore S200 Evaluation Software and are presented in Table 2. 
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Figure S4. Related to Figure 3 and Experimental methods. Characterization of CDK4 and CDK6. (A, B) CDK4 
and CDK6 do not bind non-specifically to Avi-tagged beads. Uncropped SDS-PAGE gels to accompany Figure 3 to 
confirm there is no non-specific binding of CDK4 and CDK6 to Avi-tag-beads. Bars above the gels indicate inputs. (A) 
CDK4, (B) CDK6. Samples were analyzed by SDS-PAGE and visualized by InstantBlue staining. (C, D) Generation 
of GSTCDK4 and GSTCDK6 complexes from insect cells. (C) Silver stained SDS-PAGE gel of purified GSTCDK4 
and GSTCDK6. GSTCDK samples used in the HTRF assay were analyzed by SDS-PAGE and subsequent silver-
staining. Lane 1, GSTCDK4; lane 2, GSTCDK6. The lower band in the GST-CDK4 sample is a small amount of 
contaminating GST.  (D) The SfHsp90-Cdc37-CDK4 complex is disrupted by p16INK4a. SfHsp90-Cdc37-CDK4 
purified from insect cells was incubated with buffer (lane 1) or p16INK4a (lane2) and immuno-precipitated with anti-
Hsp90 antibodies.  Subsequent to SDS-PAGE samples were western blotted using anti -Hsp90, -Cdc37, -CDK4 and -
p16INK4a antibodies. CDK4 forms a stable complex with Hsp90 and Cdc37 (lane 1) but is displaced from Hsp90 upon 
addition of p16INK4a (lane 2).  Cdc37 remains associated with Hsp90 upon client kinase displacement (lane 2). Input 
samples are 10% input. 
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Supplemental Experimental Procedures 
Materials and reagents 
Terbium-labelled anti-GST antibody and streptavidin-labelled XL665 dye were purchased from Life Technologies and 
Cisbio, respectively. CDK4/6 inhibitors PD0332991 (palbociclib) was purchased from Sigma Aldrich, and LY2835219 
(abemaciclib) and LEE011 (ribociclib) from MedChem Express, and the Hsp90 ATP-competitive inhibitor NVP-
AUY922 was supplied by Santa Cruz Biotechnology. Baculovirus expression for protein production in insect cells Sf9 
was performed using the MultiBac™ system (Geneva-Biotech). 
Protein expression  
Human CDK4 and CDK6 were expressed in Sf9 insect cells using a recombinant baculovirus expression system 
(Bieniossek et al., 2012), Geneva-Biotech MultiBac™). Full length human CDK4 and CDK6 with an N-terminal 
glutathione-S-transferase (GST)-tag and 3C protease recognition site, and human untagged Cdc37(1-348) were cloned 
separately into the pACEBac1 acceptor vector. Human untagged full-length cyclin D1 and cyclin D3 were cloned into 
the pIDK donor vector. Cre recombinase (New England Biolabs) was used in the Cre-LoxP reaction of acceptor and 
donor vectors to generate the multigene fusion for co-expression of CDK4 or CDK6 with either cyclin D1 or cyclin D3. 
All constructs were verified by restriction enzyme digestion and DNA sequencing.  Approximately 5-10 ng of DNA 
vector (either pACE-BAC-1-CDK, pACE-BAC-1-Cdc37 or an acceptor-donor fusion pACE-Bac-1-pIDK for CDK and 
cyclin D co-expression) was used to transform EmBacY E. coli cells harboring the EMBacY MultiBac™ bacmid (for 
constitutive expression of yellow fluorescent protein YFP). DNA sequences of interest were transferred to the bacmid 
via transposition into the mini Tn7 attachment site. White recombinant colonies were selected for subsequent bacmid 
preparation.  MultiBac bacmid DNA was prepared by alkaline lysis (QIAprep Miniprep kit (Qiagen)). The final 
supernatant was precipitated using isopropanol (40%) and the resulting pellet was then washed twice with 70% ethanol, 
dried and re-suspended in sterilised water in sterile conditions.  For the transfection reaction, transfection reagent (Gene 
Juice™ (Novagen)) was added to the re-suspended bacmid DNA and the resulting cocktail was used to infect 0.5*106 
Sf9 cells seeded in 6-well plates. After 48-60 hr incubation at 27 oC, the supernatant was collected and positive 
transfection was verified by monitoring the appearance of yellow cells constitutively expressing the YFP gene and also 
containing the constructs of interest by fluorescence microscopy. This initial virus stock (Vo) was amplified twice and 
then used for protein expression.  
 
Other proteins were expressed from recombinant E. coli cells. Human CDK2 was expressed as a GST fusion from the 
pGEX6P-1 vector backbone (GE Healthcare) as previously described (Brown et al., 1999). The full-length DNA 
sequences encoding herpesvirus saimiri cyclin (Vcyclin) and Kaposi’s sarcoma-associated herpesvirus cyclin (Kcyclin) 
were synthesized (Integrated DNA Technologies). These sequences were sub-cloned into pGEX6P-1 to generate N-
terminal GST fusion proteins and also further modified to include either a C-terminal Avi or FLAG tag. Mutant 
p16INK4a sequences were generated by site-directed mutagenesis using the QuikChange method (Agilent 
Technologies) or by gene synthesis (Integrated DNA Technologies) and verified by sequencing. The INK sequences 
were subsequently cloned into a modified pET3d vector to produce a N-terminal His6-tagged protein that upon 3C 
cleavage generates the INK modified by a N-terminal Avi-tag. Full-length p27KIP1, p27KIP1, p21CIP1 and pRb 
fragments were expressed as GST-fusions from a pGEX6P-1 backbone.  For the pull down experiments, full-length 
Cdc37 was modified with a N-terminal 3C protease-cleavable hexa-histidine tag following cloning into a pRSETA 
vector backbone. 3C cleavage generates a Cdc37 construct with a FLAG-tag at the N-terminus. For the HTRF 
experiments, Cdc37 was expressed from a modified pET3d vector to generate C-terminally Avi-tagged proteins. The 
Hsp90β full length construct was used in this study.  This sequence was also expressed with an N-terminal 3C protease-
cleavable hexa-histidine tag from a pRSETA vector backbone and for the HTRF assay was expressed from a modified 
pET3d vector backbone to generate an N-terminally Avi-tagged protein.  
Protein purification  
Insect cells were harvested after 72 hours of infection, re-suspended in 10 mM HEPES pH 7.5, 150 mM NaCl, 10% 
glycerol, 0.5 mM EDTA, 0.5 mM TCEP (resuspension buffer) supplemented with a protease inhibitor cocktail (Roche) 
and stored at -20 oC. Cell pellets were sonicated on ice followed by centrifugation at 48254xg for 1 hr at 4 oC. The 
filtered supernatant was incubated with 1 ml of glutathione Sepharose (GE Healthcare) for 3 hr on a rocker at 4 oC. The 
Sepharose resin was then loaded into a column and exhaustively washed with 30 ml of resuspension buffer. Bound 
proteins were eluted by 20 mM gluthathione at pH 8.0, cleaved overnight with 3C protease (1:50 w/w) and then further 
purified using size exclusion chromatography (SEC) (HiLoad 16/60 Superdex 75 pg for proteins smaller than ~60 kDa 
or a 200 pg for proteins or complexes larger than ~60 kDa).  To ensure removal of any contaminating GST dimer, 
appropriate SEC fractions were pooled, incubated with glutathione Sepharose and then concentrated. 
 
Human CDK2, INKs, p21CIP1, p27KIP1, Cdc37, Hsp90β and viral cyclins were expressed in E. coli strain 
BL21STAR(DE3) (Life Technologies) (CDK2, INKs, p21CIP1, p27KIP1, Cdc37, and viral cyclins) or Rosetta (DE3) 
(Cdc37 and Hsp90β). Briefly, recombinant E. coli BL21STAR(DE3) cells were grown at 30 oC in 2xYT medium till 
OD600~0.7-0.8, induced at 18 oC by adding 0.5 mM IPTG and further incubated for 16 hr. Alternatively recombinant E. 
coli Rosetta (DE3) cells (Merck Millipore) expressing Cdc37 or Hsp90β were grown at 37 οC in LB medium till the 
OD600 reached ~0.2 and 0.6 respectively. The cells were then induced at 18 oC by adding 0.5 mM IPTG and incubated 
for 16 hr. GST-tagged proteins were first purified by an affinity chromatography step, followed by 3C protease 
cleavage to remove the GST tag and then subsequent SEC. If required, appropriate SEC fractions were pooled and re-
applied to a glutathione column to remove any contaminating GST and the flow-through collected. His6-tagged proteins 
were purified using Ni-NTA His-Trap (GE Healthcare), cleaved and further purified using sequential SEC and ion 
exchange chromatography (HiTrap Q, GE Healthcare). Protein concentrations were determined by NanoDrop2000 UV-
Vis Spectrophotometer (Thermo Scientific) or using a Shimadzu UV1800 spectrophotometer. A representative SDS-
polyacrylamide gel stained with silver is shown in Figure S4 to illustrate the purity of the GSTCDK4 and GSTCDK6 
post purification. 
Protein biotinylation 
Avi-tagged proteins (Cdc37, p16INK4a, p16INK4a mutants, Kcyclin and Vcyclin) were biotinylated to provide an 
affinity tag for the streptavidin-tagged XL665 dye. A substantial amount of biotinylated protein was purified from the 
recombinant E. coli cells as a result of endogenous BirA activity.   Proteins were further modified by incubating 40 µM 
of the Avi-tagged protein with 10 µg BirA in biotinylation buffer (50 mM Bicine pH 8.3, 10 mM ATP, 10 mM MgOAc, 
50 µM d-biotin) at 30°C for 60 minutes. Protein was then buffer exchanged into HTRF buffer A (50 mM HEPES pH 
7.5, 100 mM NaCl, 0.1 mg/ml BSA, 1 mM DTT) using a PD-10 desalting column (GE Healthcare).  The extent of 
protein biotinylation was monitored by pull downs using High Capacity NeutrAvidin® Agarose Resin (Thermo 
Scientific Pierce). 
Pull-down assays  
For the pull down assays presented in Figure 2C, D, 6.3 µg (0.12 nmol) of FLAG-tagged Cdc37 was incubated for 1 hr 
at 4 oC with 25 µl anti-FLAG M2 agarose beads in a total volume of 60 µl in 20 mM Tris pH 7.5, 150 mM NaCl, 5 mM 
Na2MoO4, 0.5 mM EDTA, 0.5 mM TCEP, and 0.5% Igepal. Using this buffer non-specific protein binding to the beads 
was minimized. A 3-fold molar excess (0.36 nmol) of the second protein (CDK or CDK-cyclin D was then added and 
incubation continued for a further hour at 4 oC.  Each pull down was washed three times with 200 µl of buffer and then 
15 µl of SDS-PAGE sample buffer was added. Boiled and spun down samples were subjected to SDS-PAGE and 
proteins visualized by InstantBlue staining.   
Pull-down assays of chaperone complexes assembled in insect cells  
For the pull down assays presented in Figure 2E, F, Figure 3C, D and Figure S2G and H, chaperone complexes 
containing Hsp90Sf9-Cdc37-CDK4 or Hsp90Sf9-Cdc37-CDK6 were generated by co-expressing human GSTCDK4 or 
GSTCDK6 with human untagged Cdc37(1-348) in Sf9 insect cells using the baculovirus expression system as described 
above. Complexes were purified using the GST tag on the CDK as described in Vaughan et al. (Vaughan et al., 2006). 
Chaperone complexes were separated by SEC (Superdex 200 16/60 (GE Healthcare)). Fractions containing Hsp90Sf9-
Cdc37-CDK4 or Hsp90Sf9-Cdc37-CDK6 were pooled and concentrated. For pull downs, 4.8 µg (0.150 nmol) of 
biotinylated C-terminally Avi-tagged viral cyclin K (D-type cyclin) or p16INK4a was incubated for 1 hr at 4 oC with 25 
µl NeutrAvidin® Agarose Resin in a toal volume of 60 µl (Thermo Scientific Pierce) in 20 mM Tris pH 7.5, 150 mM 
NaCl, 5 mM Na2MoO4, 0.5 mM EDTA, 0.5 mM TCEP and 0.5% Igepal. A 3-fold molar excess of chaperone complex 
purified from insect cells was added and incubated for a further hour at 4 oC. Each pull down was washed as described 
above and boiled prior to separation by SDS-PAGE. Proteins were visualized by InstantBlue staining. 
pRb kinase assay  
To assemble the various complexes, 15 µg of Cdc37 was mixed with a molar equivalent of CDK6, and incubated for 
1hour at 4 oC. Vcyclin was then added to appropriate samples at a 1:1 molar ratio CDK6:Vcyclin and incubated for a 
further hour at 4 oC. Vcyclin complexes with Cdc37 or CDK6 were generated by mixing proteins at equivalent 1:1 
molar ratios. During incubation steps, the samples were manually mixed half-way through. 200 µl of glutathione bead 
slurry was washed in pRb assay buffer (50 mM HEPES, pH7.5, 10 mM MgCl2, 1 mM DTT, 0.1 mM orthovandate, 1 
mM NaF, 0.1 mM EDTA) three times and then 1 mg of GST-pRb encoding pRb residues 379-928 (Kato et al., 1993) 
was added and incubated for 30 mins at 4 oC. The beads were pelleted, the excess supernatant removed and then re-
suspended to 200 ul volume.  20 µl of GST-pRb–bead slurry was added to each reaction tube, and the volume made up 
to 100 µl using pRb assay buffer.  The kinase reactions were initiated by the addition of ATP to a final concentration of 
2 mM, then allowed to proceed for 30 mins at 30 oC with gentle agitation. The reactions were stopped by addition of 2 x 
LDS buffer and analysed by SDS-PAGE and subsequent western blotting using an anti-phosphorylated S780 antibody 
(Abcam, ab173289).  
Homogenous time-resolved fluorescence (HTRF)  
(a) Direct binding format: In the direct binding assay format glutathione-S-transferase (GST)-tagged cyclin-dependent 
kinase (CDK) is incubated with biotinylated Avi-tagged protein of interest to form a GSTCDK-protein complex. The 
complex is then incubated with a Tb-labeled anti-GST antibody and streptavidin-tagged XL665 dye. Formation of a 
complex brings the Tb and XL665 into proximity so that excitation of the Tb results in emission from the XL665 dye as 
a result of Förster resonance energy transfer (FRET) between the two probes. To optimize the assay for direct binding 
measurements the biotinylated protein of interest was initially titrated, over 11 serial dilution points and an additional 
buffer blank point, against 5 fixed concentrations of either GSTCDK4 or GSTCDK6 (100 nM, 50 nM, 25 nM, 10 nM 
and 5 nM). Subsequently experiments to assay the various GSTCDK complexes described in Figures 1B; 4C-F; and 
Figure S2A-D were carried out at a fixed GSTCDK concentration of 10 nM. The concentration of GSTCDK2 and GST 
used in Figure S1A, B was 25 nM. Concentrations of GSTCDK and the binding protein of interest were prepared in 
HTRF buffer A (50 mM HEPES, 100 mM NaCl, 1 mM DTT and 0.1 mg/ml BSA) and incubated together for 60 
minutes at 4°C or on a shaker at room temperature. 5 nM Tb labeled anti-GST antibody and SAXL665 at 1/8th the 
concentration of the biotinylated protein, were prepared in HTRF buffer B (50 mM HEPES, 100 mM NaCl and 0.1 
mg/ml BSA) and added to each well. The plate was incubated for a further 120 minutes at 4°C, before being scanned.  
Samples were excited using a wavelength of 337 nm and emission spectra measured at 620 nm and 665 nm 
(PHERAstar FS (BMG LABTECH)). Binding curves were plotted using GraphPad Prism 6 from which the Kds were 
determined. The curves shown are representative binding curves from at least two runs with each mutant carried out on 
separate days.   
 
(b) Competition mode: 8 nM GSTCDK4 and 150 nM C-Avi Cdc37, or 6 nM GSTCDK6 and 500 nM C-Avi Cdc37 (the 
Cdc37 concentration was adjusted to the measured Kd for the CDK-Cdc37 interaction), were added to each well along 
with a serial dilution of the competitor (viral cyclins, Figure 2A, B; INKs, Figure 3A, B, E, F; CIP/KIPs, Figure 4A, B; 
ATP competitive inhibitors, Figure 1C, D; or ATP, Figure S1E, F). All dilutions were made using HTRF buffer A (50 
mM HEPES, 100 mM NaCl, 1 mM DTT and 0.1 mg/ml BSA) and set up in duplicate. ATP-competitive inhibitor stocks 
were prepared either in 100% DMSO (LEE011) or water (PD0332991 and LY2835219). LEE011 titrations were carried 
out at a final DMSO% of 0.1%.  The plate was incubated for 60 minutes at 4°C, before 0.5 nM Tb labeled anti-GST 
antibody and 18.75 nM of SAXL665 (for the CDK4 measurements) or 3 nM Tb labeled anti-GST antibody and 62.5 
nM of SAXL665 (for the CDK6 measurements), were added to each well. Concentrations of the Tb antibody and 
SAXL665 were made up using HTRF buffer B (50 mM HEPES, 100 mM NaCl and 0.1 mg/ml BSA). The plate was 
incubated for a further 120 minutes at 4°C, before being scanned. Samples were excited using a wavelength of 337 nm 
and emission spectra measured at 620 nm and 665 nm (PHERAstar FS (BMG LABTECH)). Percentage inhibition 
graphs were plotted using GraphPad Prism 6, by comparing to a maximum signal, where no competitor is present, and a 
minimum signal, where no GSTCDK4 or GSTCDK6 is present.  
Surface Plasmon Resonance (SPR) 
All SPR experiments were performed on a Biacore S200 (GE Healthcare) at 4 °C using SPR buffer (10 mM HEPES pH 
7.5, 150 mM NaCl, 3 mM EDTA and 0.05% Tween 20). Samples were centrifuged at 10000 x g for 10 minutes at 4 °C 
before use. 40 µg/mL GSTCDK4 or 30 µg/mL GSTCDK6 were captured on a surface of goat anti-GST antibody (GE 
Healthcare) at 5 µL/min for 600s. Antibody capture to the CM5 BIAcore sensor chip was via amine coupling using the 
standard protocol provided in the GST capture kit (GE Healthcare). Analyte solutions of p16INK4a and p16INK4a 
mutants at 200 nM, 100 nM, 25 nM, 6.25 nM and 1.56 nM were flowed over the bound GSTCDKs at 30 µL/min for 
240s and the dissociation was measured over 600s. Analyte solution of Cdc37 at 4000 nM, 2000 nM, 1000 nM, 250 nM 
and 62.5 nM were flowed over for 700s and the dissociation measured at 600s. In case of viral cyclins: 500 nM, 250 
nM, 62.5 nM, 15.6 nM and 4 nM for 600s and dissociation was measured at 600s. The bound GSTCDKs were removed 
from the antibody using 10 mM glycine pH 2.1 at 30 µL/min for 240s. The chip was regenerated by capturing fresh 
GSTCDKs before each analyte concentration run. GST was loaded onto a separate lane at 10 µg/mL for 120s at 5 
µL/min to act as a negative control. Sensorgram readings from the GST control were subtracted from GSTCDK 
sensorgrams to correct for non-specific interactions and bulk effects. Kd values and dissociation rates were calculated 
using the Biacore S200 Evaluation Software. 
Differential Scanning Fluorimetry 
A protein/Sypro orange mix containing 5 µM protein and a 1:5,000 dilution of dye in DMSO (as supplied by Sigma 
Aldrich) was prepared just before plate setup in 10 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM EDTA and 0.5 mM 
TCEP. 14.5 µL of the protein/Sypro orange mix was aliquoted into 384-well plates and sealed. Each experiment was 
done in triplicate. Thermal melting experiments were carried out using an QuantStudio Real Time PCR machine 
(Applied Biosystems). The plates were first equilibrated at 25°C for 2 min in the PCR machine before starting the 
thermal melting experiment upon which the plates were heated at 0.05°C per second from 25 to 99°C. The fluorescence 
intensity was recorded using the ROX filters under continuous collection. Raw fluorescence data were extracted from 
the QuantStudio Real-Time PCR software and analysed using the Applied Biosystems Protein Thermal Shift software. 
Calculated derivative Tm values for each of the three repeats were extracted and the average values calculated. 
Silver staining 
3 µg of complexes GST-CDK4 or GST-CDK6 used in HTRF and SPR assays were run on 10% SDS-PAGE gel (Biorad) 
for 35 minutes in 1xTGS Buffer (Biorad) at 200 V. Subsequently gels were silver stained using Pierce Silver Stain Kit 
(ThermoScientific) using manufacturer instructions. The gel was stained until bands started appearing and stopped with 
5% acetic acid for 10 minutes, followed by 2x 5 minutes washes with ultrapure water. 
Western blotting 
SfHsp90-Cdc37-CDK4 purified from insect cells (10 µg) was incubated with buffer or p16INK4a (20 µg) for 60 
minutes on ice and immuno-precipitated with anti-Hsp90 antibodies (abcam AC88 #ab13492) overnight. Bead bound 
proteins were washed 3x times with Lysis/Wash buffer (ThermoFisher Scientific, #26146).  Subsequent to SDS-PAGE 
samples were western blotted using anti -Hsp90 (Cell Signaling, #4874), -Cdc37 (ThermoFisher Scientific, C1 #MA3-
029), -CDK4 (Cell signaling, CDK4 (D9G3E) #12790) and -p16INK4a (Abcam, DCS50.1, #ab16123) antibodies.  
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